SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN™, a minimally invasive diagnostic test to identify …
A significant barrier in Alzheimer’s Disease (AD) research for decades has been the inability to identify AD in people recently diagnosed with dementia and to distinguish AD from other forms of dementia. But as presented at the 2022 Alzheimer’s Association International Conference (AAIC) July 31-August 4, data have been presented to address that barrier. SYNAPS …
ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), has released data on the performance of the Morphometric Imaging (MI) assay of the DISCERN test at the Alzheimer’s Association International Conference (AAIC), July 31 – Aug. 4, 2022, San Diego. …
Input your search keywords and press Enter.
Recent Comments